Our news
Current news
:: 04. May 2020
INNODIA receives €12m grant to start HARVESTing
INNODIA, a public/private partnership for research aiming at biomarker discovery and prevention of type 1 diabetes in Europe, won a €12m grant from the European Commission’s Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU).
:: 12. March 2020
We welcome a new INNODIA Satellite in Geel, Belgium
As Type 1 diabetes consultants in UZ Leuven, Dr. Bernard Peene and myself receive first-hand information about the latest and most innovative therapies and Type one diabetes devises (different types of pumps & CGM monitoring systems).
News 2019
:: 22. November 2019
Fruitful Annual Meeting Sicily
This year’s annual INNODIA meeting took place in the Ettore Majorana Foundation and International Centre for Scientific Culture in beautiful Erice, an old pre-mediaeval city where three restored monasteries provide an appropriate setting for high intellectual endeavour.
:: 18. June 2019
Final visit of first participant recruited in the Study
Cambridge - April 1st was a very special day for INNODIA. Not because of April Fools’ Day, but because it was the last visit of Annabelle, a very courageous young woman, the first participant with Type 1 Diabetes recruited in the INNODIA study.
:: 03. April 2019
Engagement of people living with T1D and their families
Partners of INNODIA are accountable for a growing number of high level, collaborative papers, in our strive to discover novel biomarkers for T1D and achieving a better understanding of the pathogenesis of the disease, thus leading to a path for prevention and cure.
:: 07. January 2019
INNODIA was present at the IMI networking event!
On the 14th of December, INNODIA attended the IMI networking event in Dudelange, Luxembourg. This international conference was organized by Luxinnovation and its partners, the Integrated Biobank of Luxembourg, the Laboratoire national de santé, and the Luxembourg Institute of Health in order to celebrate the 10th anniversary of the Innovative Medicines Initiative Joint Undertaking (IMI-JU). IMI-JU is responsible for the funding of medical research projects such as INNODIA.
Archive
:: 13. August 2018
Do pancreatic beta cells facilitate their own destruction?
study led by R. Mallone has identified the molecules presented by pancreatic beta cells that mediate their abnormal recognition by the immune system and lead to their destruction in type 1 diabetes (T1D). These discoveries change...
:: 02. July 2018
Frequent monitoring of c-peptide levels
INNODIA researchers from Cambridge have developed a method to monitor what happens to the ability of type 1 diabetes patients to produce their own insulin over time, at home. They asked 32 children and adolescents with type 1 diabetes to collect a drop of blood at home on a filter paper card, also called ‘dried blood spot’, every week, in the first year from diagnosis.
:: 02. July 2018
Full day meeting at King’s College in London
Last Tuesday, around 60 nurses, clinicians and researchers from 12 different European countries gathered for a full day meeting at King’s College, London, to discuss the progress on the INNODIA clinical study. Members of the communication team, representatives of JDRF and the Patient Advisory Committee also attended the meeting.
:: 05. February 2018
We are not all type 1 diabetic, but we are all ‘auto-immune’!
In an article published on Feb, 2nd 2018 in Science Immunology, INNODIA Investigators report that the self-directed autoimmune T lymphocytes that engender the islet destruction of T1D circulate in all individuals, whether diabetic or not, but reach the pancreas only in T1D patients.
"Ariyana Salek is a 10 year old – she developed Type 1 Diabetes (T1D) at the age of 6 years old. Her brother Arman (7 years old) and mother Tracey have volunteered to join INNODIA. The volunteers give a small amount of blood to see if they have the characteristic antibodies suggesting future risk for developing T1D".
Coordinator:
Prof. Chantal Mathieu, KU Leuven